- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cancers
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 336KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 52KB)
Bevacizumab – March 2022
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Bevaciptin®
Last updated
1 July 2022